ITI 1549
Alternative Names: ITI-1549Latest Information Update: 15 Jan 2024
At a glance
- Originator Intra-Cellular Therapies
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psychiatric disorders
Most Recent Events
- 05 Dec 2023 Preclinical trials in Psychiatric disorders in USA (unspecified route) prior to December 2023
- 05 Dec 2023 Pharmacodynamics and adverse event data from a preclinical trial in Psychiatric disorders released by Intra-Cellular Therapies
- 05 Dec 2023 Intra-Cellular Therapies expected to enter human testing in late 2024 or early 2025.